pan-cancer drivers of Notch and Hedgehog. GISTIC datasets were used to evaluate copy 23 number alterations. Receiver operating characteristic and Cox regression were employed for 24 survival analyses. 25
Results: 26
We identified a Notch-Hedgehog signature of 13 genes exhibiting high frequencies of somatic 27 amplifications leading to transcript overexpression. The signature successfully predicted 28 patients at risk of death in five cancers(n=2,278): glioma(P<0.0001), clear cell renal 29 cell(P=0.0022), papillary renal cell(P=0.00099), liver(P=0.014) and stomach(P=0.011). The 30 signature was independent of other clinicopathological parameters and offered additional 31 resolution to stratify similarly-staged tumours. High-risk patients exhibited features of 32 stemness and had more hypoxic tumours, suggesting that hypoxia may influence CSC 33 behaviour. Notch-Hedgehog + CSCs had an immune privileged phenotype associated with 34 increased regulatory T cell function. 35 homeostasis, morphogenesis and cell fate determination (TGF-β, Wnt, Notch and Hedgehog) 48 are often seen in CSCs. These pathways rarely act in isolation and significant crosstalk between 49 them have been reported 5 . 50
51
In order to fully exploit these pathways for CSC therapy, pan-cancer explorations are warranted 52 to reveal conserved components that can be prioritised as therapeutic targets. Concentrating 53 on Notch and Hedgehog signalling pathways, we seek to attain a comprehensive 54 understanding of how somatic copy number alterations and expression profiles of pathway 55 genes along with their downstream targets could influence tumour progression and prognosis. 56
The role of Notch signalling in oncogenesis was initially discovered in T cell acute lymphoblastic 57 leukaemia 6 . Since then, multiple studies on Notch signalling have demonstrated both 58 oncogenic and tumour suppressive functions in haematological and solid malignancies, 59
implying its pleiotropic nature that is very much dependent on cellular types 7 . Hedgehog is a 60 morphogen that regulates a signalling cascade involving the Smoothened protein to influenceKEGG pathway analyses on DEGs demonstrated enrichments of pathways involved in 259 regulating self-renewal and pluripotency, i.e. Wnt, TGF-β, MAPK, JAK-STAT and PPAR signalling 260 ( Fig. 3D; Fig. S3B ), suggesting that tumours with hyperactive Notch-Hedgehog signalling were 261 characterised by molecular footprints of stemness and that there was significant crosstalk 262 between Notch-Hedgehog and other pathways involved in controlling tumour initiation. 263
Additionally, Gene Ontology analyses revealed significant enrichments of processes related to 264 cell differentiation, cell proliferation, embryo development and morphogenesis (Fig. 3D) , 265 supporting the hypothesis that tumour aggression and elevated mortality could be caused by 266 the presence of cancer stem cells (CSCs) that are likely to be refractory to therapy. Consistent 267 with these results, Enrichr transcription factor (TF) analyses revealed that TFs associated with 268 stem cell function appeared amongst top enriched candidates (Fig. 3D ). DEGs were enriched 269 as binding targets of SUZ12, REST, EZH2, SMAD4 and FOXM1 as supported by both ChEA and 270 ENCODE databases (Fig. 3D ). Binding targets of SUZ12 and EZH2 were consistently enriched 271 across all five cancer types, while targets of REST and SMAD4 were enriched in all cancers 272 except for clear cell renal cell carcinoma (Fig. 3D ). These TFs were thought to induce epithelial-273 mesenchymal transition and promote invasion and metastasis consistent with their roles in 274 tumour initiation and maintenance [26] [27] [28] . 275
276
To independently confirm that the 13-gene signature is a potential pan-cancer marker of CSCs, 277
we performed Spearman's correlation analyses to compare 13-gene scores with expression 278 profiles of other CSC markers where we would expect to see positive correlations. We 279 examined expression profiles of nine genes implicated in CSC regulation: CD105, CD133, 280 CD200, CD24, CD29, CD44, CD73, CD90 and NESTIN. Putative neural CSC markers are CD133, 281 NESTIN, CD105 and CD44 29 . We observed significant positive correlations between 13-gene 282 scores and all four markers in glioma samples (Fig. S4) . CD105, CD29, CD44, CD73, CD90 and 283 NESTIN were positively correlated with 13-gene scores in renal cancers (Fig. S4) ; an observation 284 which is consistent with these genes being markers of renal CSCs 30 . Seven and four CSC 285 markers were positively correlated with 13-gene scores in liver and stomach cancers 286 respectively (Fig. S4) . Given the tissue-specific nature of these genes, we would not expect to 287 see positive correlations in all cases. Nonetheless, our results overall suggest that hyperactive 288 Notch-Hedgehog signalling is associated with CSC phenotypes, contributing to tumour 289 aggression and poor survival outcomes. 290
292
Transcription factors involved in self-renewal processes influence survival outcomes in 293 patients with hyperactive Notch-Hedgehog signalling 294
295
Previously, we observed that binding targets of TFs associated with stem cell function were 296 enriched amongst DEGs (Fig. 3D ). Polycomb proteins, EZH2 and SUZ12 have been implicated 297 in CSC formation and maintenance 31, 32 . REST is a transcriptional repressor involved in 298 maintaining embryonic and neural stem cell phenotypes 33 . Given their roles in CSC 299 maintenance, we would expect to see elevated expression of these TFs in tumours with 300 hyperactive Notch-Hedgehog signalling. Indeed, we observed significant positive correlations 301 between 13-gene scores and EZH2 levels in glioma (rho=0.45; P<0.0001), clear cell renal cell 302 (rho=0.22; P<0.0001), papillary renal cell (rho=0.33; P<0.0001) and liver (rho=0.26; P<0.0001) 303 cancers (Fig. 4A) . Additionally, in the glioma cohort, positive associations between 13-gene 304 scores and REST (rho=0.39; P<0.0001) or SUZ12 (rho=0.17; P<0.0001) profiles were observed 305 (Fig. 4D) . 306
To determine whether these associations harboured prognostic information, patients were 308 categorised by their 13-gene scores and expression profiles of individual TFs into four 309 categories: 1) high 13-gene score and high TF expression, 2) high 13-gene score and low TF 310 expression, 3) low 13-gene score and high TF expression and 4) low 13-gene score and low TF 311 expression ( Fig. 4A and 4D) (Fig. 6A ). As performed 367 previously, patients were separated into four groups based on their 13-gene and Treg scores. 368
When used in combination with the Notch-Hedgehog signature, Treg expression profiles 369 allowed further separation of patients into additional risk groups that influenced overall 370 survival: glioma (P<0.0001) and clear cell renal cell carcinoma (P<0.0001) (Fig. 6B) . Intriguingly, 371 patients characterised by high 13-gene and Treg scores had significantly higher mortality rates 372 compared to those with low 13-gene and Treg scores: glioma (HR=4.921, P<0.0001) and clear 373 cell renal cell carcinoma (HR=2.968, P<0.0001) (Fig. 6C ). This was also true for other histological 374 subtypes of glioma: astrocytoma (HR=2.721; P=0.0032), oligoastrocytoma (HR=5.431; 375 P=0.0091) and glioblastoma (HR=3.065; P=0.0068) (Fig. 6C) Hedgehog driver genes that were recurrently amplified and overexpressed, we found that 399 these genes were associated with clinically relevant molecular features of stemness. The 400 biological consequences of elevated expression of driver genes were manifold. High-risk 401 patients showed overexpression of genes associated with other stem cell-related pathwayssuch as Wnt, JAK-STAT and TGF-β signalling ( Fig. 3D. and into TNM stage and then median-stratified into low-and high-score groups based on their 13-682 gene scores. P values were determined using the log-rank test. (B) Kaplan-Meier estimates for 683 overall survival using the signature on glioma subtypes ranging from low-grade (astrocytoma, 684 oligoastrocytoma) to high-grade gliomas (glioblastoma multiforme). Patients were first 685 stratified by histological subtypes followed by quartile stratification into Q1 (<25%), Q2 (25-686 50%), Q3 (50-75%) and Q4 (>75%) based on their 13-gene scores. P values were determined 687 using the log-rank test. (C) Predictive performance of the signature. The receiver operating 688 characteristic (ROC) analysis was used to assess specificity and sensitivity of the signature in 689 predicting 5-year overall survival. ROC curves generated from the signature were compared tothose generated from TNM staging and a combined model uniting TNM stage and the 691 signature. AUCs for TNM stage were in accordance with previous publications employing TCGA 692 
738
CSCs were also determined in histological subtypes of glioma (astrocytoma, oligoastrocytoma 739 and glioblastoma multiforme). (C) Figure S1 . Prognosis of each of the 13 signature genes in 20 cancer types determined using 746
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